CA2993624A1 - Procede pour diagnostiquer un cancer ou une thrombose associee a un cancer en mesurant les concentrations plasmatiques de h3cit - Google Patents
Procede pour diagnostiquer un cancer ou une thrombose associee a un cancer en mesurant les concentrations plasmatiques de h3cit Download PDFInfo
- Publication number
- CA2993624A1 CA2993624A1 CA2993624A CA2993624A CA2993624A1 CA 2993624 A1 CA2993624 A1 CA 2993624A1 CA 2993624 A CA2993624 A CA 2993624A CA 2993624 A CA2993624 A CA 2993624A CA 2993624 A1 CA2993624 A1 CA 2993624A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- h3cit
- plasma
- biomarker
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1500330 | 2015-08-07 | ||
| SE1500330-4 | 2015-08-07 | ||
| SE1551074-6 | 2015-08-14 | ||
| SE1551074 | 2015-08-14 | ||
| PCT/US2016/045781 WO2017027379A1 (fr) | 2015-08-07 | 2016-08-05 | Procédé pour diagnostiquer un cancer ou une thrombose associée à un cancer en mesurant les concentrations plasmatiques de h3cit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2993624A1 true CA2993624A1 (fr) | 2017-02-16 |
Family
ID=56684305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2993624A Abandoned CA2993624A1 (fr) | 2015-08-07 | 2016-08-05 | Procede pour diagnostiquer un cancer ou une thrombose associee a un cancer en mesurant les concentrations plasmatiques de h3cit |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3332257A1 (fr) |
| AU (1) | AU2016307448A1 (fr) |
| CA (1) | CA2993624A1 (fr) |
| WO (1) | WO2017027379A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3886838A4 (fr) | 2018-11-30 | 2022-08-10 | Beth Israel Deaconess Medical Center, Inc. | Compositions et méthodes pour réduire les événements thrombotiques majeurs chez les patients cancéreux |
| GB201906199D0 (en) * | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| CN112773805B (zh) * | 2019-11-11 | 2024-05-10 | 中国科学院脑科学与智能技术卓越创新中心 | 缺血性脑损伤的新型治疗药物 |
| EP4072673A4 (fr) * | 2019-12-09 | 2024-02-21 | Beth Israel Deaconess Medical Center, Inc. | Compositions et procédés d'identification et de modulation d'états thrombotiques chez un patient atteint d'un cancer |
| CN112881704A (zh) * | 2020-12-30 | 2021-06-01 | 中山大学 | Cit-h3蛋白的检测试剂在制备肝癌预后和/或复发预测试剂中的应用 |
| CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
| WO2023170724A1 (fr) * | 2022-03-08 | 2023-09-14 | The University Of Jordan | Utilisation de dérivés de quinolone substitués pour traiter le cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0413732D0 (en) * | 2004-06-13 | 2004-07-21 | Chroma Therapeutics Ltd | Histone modification |
-
2016
- 2016-08-05 CA CA2993624A patent/CA2993624A1/fr not_active Abandoned
- 2016-08-05 EP EP16751130.2A patent/EP3332257A1/fr not_active Withdrawn
- 2016-08-05 WO PCT/US2016/045781 patent/WO2017027379A1/fr active Application Filing
- 2016-08-05 AU AU2016307448A patent/AU2016307448A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017027379A1 (fr) | 2017-02-16 |
| EP3332257A1 (fr) | 2018-06-13 |
| AU2016307448A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2993624A1 (fr) | Procede pour diagnostiquer un cancer ou une thrombose associee a un cancer en mesurant les concentrations plasmatiques de h3cit | |
| ES2839456T3 (es) | Proteína 2 que contiene el dominio del esperma móvil y del cáncer | |
| US20230298695A1 (en) | Methods for prostate cancer detection and treatment | |
| JP6055764B2 (ja) | 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー | |
| US8580519B2 (en) | Use of plasma HSP90 related to malignancy | |
| BR112015009961B1 (pt) | proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende | |
| EP3743534B1 (fr) | Méthodes de détection de cancer du côlon et de suivi de traitement | |
| EP2596364B1 (fr) | Biomarqueurs du plasma sanguin pour des polythérapies à base de bevacizumab, dans le traitement du cancer du pancréas | |
| US11744907B2 (en) | Predicting peptide receptor radiotherapy using a gene expression assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20190806 |